Mardi Dier bought stock once, on May 9, 2023

Mardi C. Dier is an Executive Vice President and Chief Financial Officer at Madrigal Pharmaceuticals, Inc. (MDGL), where she serves as the company’s principal financial and accounting officer and leads its financial strategy, planning, and capital markets activities.( She joined Madrigal in early 2024, initially as a senior advisor before being appointed CFO, bringing more than 20 years of executive financial leadership experience in the biopharmaceutical industry, including extensive work in corporate strategy, FP&A, global supply chain, investor relations, and business development.(

Before Madrigal, Dier held senior finance roles at several life sciences companies, serving as Chief Financial Officer of Acelyrin, Inc., where she helped complete a $621 million initial public offering, and previously as Executive Vice President and Chief Financial Officer of Ultragenyx Pharmaceutical Inc., overseeing strategy, finance, accounting, tax, investor relations, communications, and IT functions during a period of significant global growth.( Earlier, she spent 14 years at Portola Pharmaceuticals in CFO and Chief Business Officer roles, and held positions at Chiron Corporation, Prudential Securities, and KPMG.( Dier serves on the boards of ORIC Pharmaceuticals, Prelude Therapeutics, Synthekine, and HealthCare Royalty, and on the Board of Advisors of the UCLA Anderson School of Management.( She holds a B.S. in biology from Stanford University and an M.B.A. from UCLA Anderson School of Management.(

Written by Perplexity from public sources.